Advertisement

Topics

Dynavax's Hep B Vaccine Finally Clears US FDA With Clean Label But Larger Safety Study

17:29 EST 12 Nov 2017 | SCRIP

Heplisav-B labeling notes myocardial infarction imbalance in one trial but also apparent absence of a causal relationship; sponsor will conduct...

      

Related Stories

 

Original Article: Dynavax's Hep B Vaccine Finally Clears US FDA With Clean Label But Larger Safety Study

NEXT ARTICLE

More From BioPortfolio on "Dynavax's Hep B Vaccine Finally Clears US FDA With Clean Label But Larger Safety Study"

Advertisement
Quick Search
Advertisement
Advertisement